title: [Current opportunities for treatment of chronic hepatitis C in patients with HIV co-infection].
abstract: Liver diseases, mainly chronic viral hepatitis, recently have become the main cause of hospitalization and death in individuals with HIV infection. As HCV infection is predominant condition in this group of patients, treatment of hepatitis C is extremely important in halting hepatic injury. Large clinical trials (APRICOT, RIBAVIC, ACTG 5071) showed satisfactory efficacy and safety of therapy with pegylated interferon alpha and ribavirin. Other trials, searching ways to improve efficacy of chronic hepatitis C treatment in HIV co-infected individuals, are still running. Management possibilities include higher doses of ribavirin and, prolonged course of treatment. The article summarizes current state of knowledge in the field of chronic hepatitis C treatment in HIV/HCV-coinfected individuals.
authors.affiliation: Katedra i Klinika Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów, Odpornościowych Akademii Medycznej we Wrocławiu. minglot@k.pl
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Inglot
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Szymczak
authors.forename: Jacek
authors.initials: J
authors.lastname: Gasiorowski
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015897:Comorbidity; D019317:Evidence-Based Medicine; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D011044:Poland / Q000453:epidemiology; D011320:Primary Health Care / Q000458:organization & administration*; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000627:therapeutic use*; D018570:Risk Assessment
chemical_list: D019380:Anti-HIV Agents; D012254:Ribavirin; D007372:Interferons